We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
RainDance Technologies Appoints Scott Bortner Vice President of Intellectual Property
News

RainDance Technologies Appoints Scott Bortner Vice President of Intellectual Property

RainDance Technologies Appoints Scott Bortner Vice President of Intellectual Property
News

RainDance Technologies Appoints Scott Bortner Vice President of Intellectual Property

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "RainDance Technologies Appoints Scott Bortner Vice President of Intellectual Property"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

RainDance Technologies, Inc. has announced the appointment of Scott R. Bortner, Ph.D., J.D., as its new Vice President of Intellectual Property. Dr. Bortner will be responsible for strengthening and defending the IP portfolio underlying the company’s core digital droplet technology and applications for novel, non-invasive liquid biopsy research.

Dr. Bortner brings more than 25 years of experience leading teams to create, grow and protect some of the genomics industry’s largest IP portfolios, including patents, trade secrets, copyrights, and trademarks. During his career, he has held senior IP Counsel positions at leading law firms and life sciences companies including Applied Biosystems, Affymetrix and Natera.

As a senior attorney for Applied Biosystems, Dr. Bortner managed legal teams; filed patents; counseled management and scientists; performed extensive freedom to operate analyses and due diligence; drafted licenses; and managed litigation.

He also provided the patent due diligence for the $725 million acquisition of Ion Torrent in 2010. Dr. Bortner holds a Ph.D. in Microbiology and Molecular Genetics from Harvard University, a B.A. in Biochemistry from Cornell University, and a J.D. degree from Santa Clara University School of Law.

“Over the last decade, RainDance has developed and in-licensed a foundational IP portfolio with more than 180 patent applications worldwide for its core digital droplet technology and novel liquid biopsy applications,” said Dr. Bortner. “I’m honored to be part of a team that is transforming the way we analyze cell-based and cell-free biomarkers to advance genomics disease research.”

“At Applied Biosystems, Scott managed one the largest intellectual property patent positions for Next-Generation Sequencing (NGS) and PCR technologies in the genomics industry,” said Michael Hunkapiller, Ph.D., a Board Director at RainDance Technologies and former President and General Manager at Applied Biosystems. “Scott has been very successful developing and prosecuting patent portfolios and we will look to him to further capture value from RainDance’s innovative pursuits.”

Complex Genetics Made Simple
RainDance Technologies offers a full product portfolio to research cell-free and cell-based biomarkers for hereditary risk predisposition, initial detection, pathology, and residual disease. The company’s research-use products include:

• RainDrop® System: Ultra-sensitive digital PCR system for research of early detection and monitoring biomarkers for cancers, viruses, pathogens, and immune disorders.
• ThunderBolts™ Cancer Panel: Comprehensive Next-Generation Sequencing (NGS) panel enabling highly sensitive, rapid, low input and primary tumor profiling research in fresh biopsy, plasma and FFPE samples.
• ThunderStorm® System: High-throughput, fully automated NGS content enrichment solution enabling researchers to generate high-quality data on large-scale disease panels with a simple and affordable workflow.

Advertisement